Leukemia Program, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Pavilion, Philadelphia, PA, 19104, USA.
Best Pract Res Clin Haematol. 2019 Dec;32(4):101105. doi: 10.1016/j.beha.2019.101105. Epub 2019 Oct 19.
Survival rates for patients with acute myeloid leukemia (AML) older than 75 years are still quite dismal. Recent approvals, therefore, of two agents specifically to treat older patients-glasdegib and venetoclax-have created excitement among the medical community. Clinical data, particularly complete response (CR) rates and CR with incomplete hematologic recovery (CRi), look quite promising and are reviewed here. Yet the question remains whether fit elderly patients should receive combination therapy containing the newer agents, particularly since intensive chemotherapy remains the only treatment that has demonstrated the ability to achieve long-term disease-free survival.
对于 75 岁以上的急性髓系白血病 (AML) 患者，其生存率仍然相当惨淡。因此，最近批准了两种专门用于治疗老年患者的药物——glasdegib 和 venetoclax，这在医学界引起了轰动。临床数据，特别是完全缓解 (CR) 率和不完全血液学恢复的完全缓解 (CRi)，看起来非常有希望，本文对此进行了回顾。然而，问题仍然是，身体状况良好的老年患者是否应该接受含有新型药物的联合治疗，特别是因为强化化疗仍然是唯一能够证明有能力实现长期无病生存的治疗方法。
